This study was part of the European risk management plan for Instanyl ® . It was funded by Nycomed (now Takeda) who had a role in study design and in the distribution of questionnaires but not in the data collection, the analysis, and interpretation of data.
Instanyl ® (fentanyl by nasal spray) received European market authorisation in 20/07/2009 for "the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain", with precise instructions in terms of indication and posology in the summary of product characteristics (SmPC). Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.
• Few cases of abuse and almost no diversion were reported by patients.
• Misuse of Instanyl ® was widespread: -Nearly half of patients declared not having cancer; -Among those who did, indication and contraindication criteria were respected by only 1/4 and few used the drug correctly.
• There seems to be a communication deficit as to the proper prescribing of this drug and its proper use when prescribed.
Abstract#
• National cross-sectional observational study of patients with an Instanyl ® prescription and a dispensation from a non-hospital pharmacy.
• The strictly anonymous self-administered questionnaires were distributed to patients at the time of drug dispensation in community pharmacies. For this, the two main wholesalers, covering ≥ 90% of the market, distributed to all pharmacies the study specific packaging including: -The original packaging of the treatment -An information letter for the pharmacist -An information letter for the patient -And the self-administered questionnaire with a reply-paid envelope.
• There were four rounds of distribution between 27/07/2011 and 12/11/2012.
• This questionnaire collected data on: -Indication -Contraindications -Use of Instanyl ® -Previous completion of the questionnaire.
• The evaluation criteria were: -Misuse: indication/contraindications misuse and posology misuse -Abuse: use of the drug for emotional reasons, relaxation, or sleep disorders -Diversion: passing the drug to another person.
• Among the questionnaires received, eligible ones were those with at least one item completed in addition to age, gender, time since first prescription, and absence of previous completion of the questionnaire.
• Study objective: 600 eligible questionnaires. 
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The objective of the PIUS study (Patients reported Instanyl Use Study) was to investigate patient self-reported misuse, abuse, and diversion of Instanyl ® in real-life in France.
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• For posology, dose titration (weaker strength at first use or current use of the weakest strength) was respected by 75.0% of patients, but 65.1% did not respect at least one of the 4 recommendations regarding the frequency of use (Table 2 ).
• Among the 160 patients who declared having cancer, 94.4% declared misuse: -75.6% declared at least one indication/contraindications misuse -and 85.6% at least one posology misuse (Table 3) .
Widening the definition of use for breakthrough pain to use for both breakthrough pain and chronic pain in cancer patients, indication/contraindications misuse was reduced (62.5%), but when posology misuse was also considered, there was no marked change in overall misuse (93.1%).
• Abuse of Instanyl ® was reported by 21 patients (15 with cancer and 6 without).
• Diversion was reported by 2 patients (1 with cancer et 1 without).
